PAVmed (NASDAQ:PAVM) Posts Quarterly Earnings Results, Beats Estimates By $0.26 EPS

PAVmed (NASDAQ:PAVM) announced its earnings results on Friday. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.26, Zacks reports. PAVmed had a negative return on equity of 126.43% and a negative net margin of 10,794.64%.

Here are the key takeaways from PAVmed’s conference call:

• Medicare reimbursement for EsoGuard is now being received consistently at the full rate through claim-by-claim adjudication, though the company said this currently applies to two Medicare patients nationwide. Lucid reported October as a record month for test volume as it shifts its commercial focus toward Medicare patients.
• Veris enrollment at Ohio State nearly doubled from July to September, with rollout underway across most departments at the cancer center. The implantable monitor remains on track for an FDA 510(k) submission in early 2027, with a 90-day animal study underway.
• PAVmed is pursuing FDA guidance on PortIO’s regulatory pathway, with a formal pre-submission meeting planned for January; a 510(k) route could mean a shorter timeline and lower capital needs than De Novo, but remains uncertain. Octeris’ next-generation probe is ready for clinical testing, with initial enrollment expected to begin in January.
• PAVmed reported $8.9 million of cash at September 30, including $5.3 million restricted, and approximately $2.8 million of quarterly burn. It failed a collateral-coverage covenant tied to Lucid shares, though the noteholder waived it through the SEC filing date; the company has a $15 million senior secured note bearing 15% interest.

PAVmed Price Performance

Shares of PAVM traded up $0.29 during mid-day trading on Friday, hitting $1.63. 56,437 shares of the company were exchanged, compared to its average volume of 300,912. The stock has a market cap of $13.04 million, a price-to-earnings ratio of -0.10 and a beta of 0.92. PAVmed has a 1-year low of $1.17 and a 1-year high of $28.44. The company has a 50 day moving average of $2.94 and a 200-day moving average of $6.25. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.19 and a current ratio of 1.19.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of PAVmed in a research note on Thursday. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, PAVmed presently has a consensus rating of “Hold” and a consensus price target of $56.00.

About PAVmed

PAVmed Inc. is a diversified medical technology company that develops and commercializes diagnostic and therapeutic products intended to address significant unmet needs in healthcare. Its portfolio has included medical devices, diagnostic technologies and digital health solutions, with a focus on products designed to improve disease detection, treatment and patient care. One of PAVmed’s principal areas of activity has been its relationship with Lucid Diagnostics, a subsidiary focused on early detection of esophageal disease.